Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2019
Home
2019
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 3B New issue annoucement, application for quotation of additional securities and agreement
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 4C Query
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid signs distribution agreement for Evolis in South Korea
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Patent for Improved Midkine Antibody Allowed in Europe
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
FY2019 Financial Results
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 4E and FY19 Financial Report
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
FY19 Results Presentation
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
2019 Annual Report to shareholders
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid receives $840K R&D Tax Credit
Prev page
1
2
3
4
5
6
Next page
